FindTrial
Sign In

Broad Effectiveness: Study With Aripiprazole

Broad Effectiveness: Study With Aripiprazole

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00036361
Enrollment
444
Registered
2002-05-10
Start date
2002-07-31
Completion date
2003-01-31
Last updated
2013-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizoaffective Disorder, Schizophrenia

Brief summary

The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders

Interventions

DRUGAripiprazole

Sponsors

Otsuka America Pharmaceutical
CollaboratorINDUSTRY
Otsuka Pharmaceutical Development & Commercialization, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with Schizophrenia or Schizoaffective Disorder

Design outcomes

Primary

MeasureTime frame
Safety Assessments—

Secondary

MeasureTime frame
Safety Assessments—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026